{"id":"frsw107","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, FRSW107 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"FRSW107 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:27.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06136507","phase":"PHASE3","title":"Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Gensciences lnc.","startDate":"2026-12-25","conditions":"Severe Hemophilia A","enrollment":76},{"nctId":"NCT04456387","phase":"PHASE3","title":"An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.","status":"COMPLETED","sponsor":"Zhengzhou Gensciences Inc","startDate":"2020-10-15","conditions":"Hemophilia A","enrollment":119},{"nctId":"NCT04845399","phase":"PHASE3","title":"Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A","status":"COMPLETED","sponsor":"Zhengzhou Gensciences Inc","startDate":"2021-04-16","conditions":"Hemophilia A","enrollment":101},{"nctId":"NCT05251090","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection","status":"COMPLETED","sponsor":"Jiangsu Gensciences lnc.","startDate":"2021-06-16","conditions":"Hemophilia A","enrollment":13},{"nctId":"NCT03747653","phase":"","title":"A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection","status":"UNKNOWN","sponsor":"Kaifeng Pharmaceutical (Group) Co., Ltd.","startDate":"2019-03-08","conditions":"Hemophilia A","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant Human Coagulation Factor Ⅷ，Fc Fusion Protein for Injection","Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection"],"phase":"phase_3","status":"active","brandName":"FRSW107","genericName":"FRSW107","companyName":"Jiangsu Gensciences lnc.","companyId":"jiangsu-gensciences-lnc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FRSW107 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}